FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis
-
By
-
May 1, 2026
Objective:
To investigate the role of FOXM1 in epithelial disruption in eosinophilic esophagitis (EoE) and assess its potential as a therapeutic target, which may lead to improved patient outcomes.
Key Findings:
- FOXM1 is identified as a key transcriptional regulator in EoE, linked to epithelial disruption, with implications for targeted therapies.
- Inhibition of FOXM1 restores epithelial differentiation and reduces proliferation, suggesting a pathway for therapeutic intervention.
- FOXM1 inhibition improves barrier integrity and mitigates inflammation in EoE models, indicating potential for clinical application.
Interpretation:
Targeting FOXM1 may provide a dual therapeutic strategy addressing both epithelial and immune dysregulation in EoE, potentially leading to improved patient outcomes through enhanced mucosal healing.
Limitations:
- The study primarily utilizes in vitro and murine models, which may not fully replicate human EoE pathology, particularly in terms of immune response and tissue architecture.
- Long-term effects and safety of FOXM1 inhibition in humans remain to be established, necessitating further clinical investigation.
Conclusion:
Inhibiting FOXM1 presents a promising therapeutic avenue for restoring epithelial homeostasis and reducing inflammation in eosinophilic esophagitis, potentially transforming patient management.
